Cover Image
Market Research Report
Product code 
1096476

US Biosimilar Market: Insights & Forecast with Potential Impact of COVID- 19 (2022-2026)

Published: | Koncept Analytics | 108 Pages | Delivery time: 1-2 business days

Price

Back to Top
US Biosimilar Market: Insights & Forecast with Potential Impact of COVID- 19 (2022-2026)
Published: July 1, 2022
Koncept Analytics
Content info: 108 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The US biosimilar market is forecasted to reach US$36.16 billion in 2026, experiencing growth at a CAGR of 40.16% during the period spanning from 2022 to 2026. Growth in the US biosimilar market is supported by factors such as rising prevalence of cancer, growing geriatric population and favorable environment. However, the market growth is expected to be restrained by complexities in manufacturing, excess competition and complexities in pricing.

The US biosimilar market by drug class can be segmented as follows: monoclonal antibodies, filgrastim & pegfilgrastim and others. In 2021, the dominant share of the US biosimilar market was being held by monoclonal antibodies, followed by filgrastim & pegfilgrastim. As of 2021, there are around 90 biosimilar products in the pipeline and 33 approved biosimilar products in the US.

The US biosimilar market by product can be categorized as follows: Prolia (Denosumab), Xolair (Omalizumab), Rituxan (Rituximab), Humira (Adalimumab) and Stelara (Ustekinumab). The US Biosimilar market landscape by class can be categorized as follows: Supportive Care, Oncology, Long Acting Insulin, Rapid Acting Insulin, Ophthalmology and TNF blockers. Factors such as patent expiry Of biologics and research on new indications has been supporting the US biosimilar market.

The COVID-19 pandemic has introduced new challenges for the pharmaceutical industry, including makers of biosimilars. The pandemic threatened to derailed product pipelines. During the height of the outbreak, resources were diverted away from the research and development of new biosimilars and towards the fight against Covid-19.

Scope of the report:

  • The report provides a comprehensive analysis of the US biosimilar market with impact of COVID-19.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Novartis AG, Amgen Inc., Samsung Biologics Co., Ltd., Celltrion, Inc. and Viatris Inc.) are also presented in detail.

Key Target Audience:

  • Biosimilar Companies
  • Biologics Companies
  • Hospitals
  • Consumers
  • Pharmaceutical companies
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Biosimilar
    • 1.1.1 Biosimilar- Introduction
    • 1.1.2 Need for Biosimilars
  • 1.2 Difference between Biologic, Biosimilar and Generic Drugs
  • 1.3 FDA-Approved Biosimilar Products
  • 1.4 Applications of Biosimilar
  • 1.5 Advantages of Biosimilar
  • 1.6 Disadvantages of Biosimilar
  • 1.7 Biosimilar Development

2. Impact of COVID- 19

  • 2.1 Impact of COVID-19 on the US Biosimilar Market
  • 2.2 Delayed Approvals
  • 2.3 Inaccessibility Of Healthcare Providers (HCPs)
  • 2.4 Postponement of Inspection
  • 2.5 Decrease in Prices
  • 2.6 Post-COVID Scenario

3. The US Market Analysis

  • 3.1 The US Biosimilar Market Forecast by Value
  • 3.2 The US Biosimilar Market by Drug Class
  • 3.3 The US Biosimilar Approvals
  • 3.4 The US Biosimilar Launches
  • 3.5 The US Biosimilar in Pipeline
  • 3.6 The US Biosimilar Market by Product
    • 3.6.1 The US Prolia (Denosumab) Biosimilar Market Forecast by Value
    • 3.6.2 The US Xolair (Omalizumab) Biosimilar Market Forecast by Value
    • 3.6.3 The US Rituxan (Rituximab) Biosimilar Market Forecast by Value
    • 3.6.4 The US Humira (Adalimumab) Biosimilar Market Forecast by Value
    • 3.6.5 The US Stelara (Ustekinumab) Biosimilar Market Forecast by Value
  • 3.7 The US Biosimilar Market Landscape
    • 3.7.1 The US Supportive Care Biosimilar Market Landscape
    • 3.7.2 The US Oncology Biosimilar Market Landscape
    • 3.7.3 The US Long Acting Insulin Biosimilar Market Landscape
    • 3.7.4 The US Rapid Acting Insulin Biosimilar Market Landscape
    • 3.7.5 The US Ophthalmology Biosimilar Market Landscape
    • 3.7.6 The US TNF blockers Biosimilar Market Landscape
  • 3.8 The US Biosimilar Pipeline Landscape
    • 3.8.1 The US Supportive Care Biosimilar Pipeline Landscape
    • 3.8.2 The US Oncology Biosimilar Pipeline Landscape
    • 3.8.3 The US Insulin Biosimilar Pipeline Landscape
    • 3.8.4 The US Ophthalmology Biosimilar Pipeline Landscape
    • 3.8.5 The US TNF blockers Biosimilar Pipeline Landscape
    • 3.8.6 The US Immunosuppressant Biosimilar Pipeline Landscape
    • 3.8.7 The US Bone Health Biosimilar Pipeline Landscape
    • 3.8.8 The US Growth Hormone Biosimilar Pipeline Landscape
    • 3.8.9 The US Infertility Biosimilar Pipeline Landscape

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Rising Prevalence of Cancer
    • 4.1.2 Increasing Health Expenditure
    • 4.1.3 Growing Geriatric Population
    • 4.1.4 Payors Favoring Biosimilars
    • 4.1.5 Cost Effective
    • 4.1.6 Favorable Environment
  • 4.2 Key Trends & Developments
    • 4.2.1 Patent Expiry of Biologics
    • 4.2.2 Research on New Indications
  • 4.3 Challenges
    • 4.3.1 Complexities in Manufacturing
    • 4.3.2 Excess Competition
    • 4.3.3 Complexities in Pricing

5. Competitive Landscape

  • 5.1 Global Market
    • 5.1.1 Revenue Comparison- Key Players
    • 5.1.2 Market Capitalization Comparison- Key Players
    • 5.1.3 FDA Approved Biosimilars- Key Players
    • 5.1.4 Forecasted Market Share - Key Players
    • 5.1.5 Biosimilar Cancellation Cases- Key Players
    • 5.1.6 Avastin (Bevacizumab) Biosimilar Developers
    • 5.1.7 Prolia (Denosumab) Biosimilar Developers
    • 5.1.8 Rituxan (Rituximab) Biosimilar Developers
    • 5.1.9 Stelara (Ustekinumab) Biosimilar Developers
    • 5.1.10 Humira (Adalimumab) Biosimilar Developers
    • 5.1.11 Xolair (Omalizumab) Biosimilar Developers

6. Company Profiles

  • 6.1 Celltrion, Inc.
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Samsung Biologics Co., Ltd.
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Amgen Inc.
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Pfizer Inc.
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies
  • 6.5 Novartis AG
    • 6.5.1 Business Overview
    • 6.5.2 Financial Overview
    • 6.5.3 Business Strategies
  • 6.6 Viatris Inc.
    • 6.6.1 Business Overview
    • 6.6.2 Financial Overview
    • 6.6.3 Business Strategies

List of Figures

  • Applications of Biosimilar
  • Advantages of Biosimilar
  • Disadvantages of Biosimilar
  • Biosimilar Development
  • The US Biosimilar Market Forecast by Value (2021-2026)
  • The US Biosimilar Market by Drug Class (2021)
  • The US Biosimilar Approvals (2015-2021)
  • The US Biosimilar Launches (2015-2021)
  • The US Biosimilar in Pipeline (As of 2021)
  • The US Prolia (Denosumab) Biosimilar Market Forecast by Value (2018-2025)
  • The US Xolair (Omalizumab) Biosimilar Market Forecast by Value (2018-2025)
  • The US Rituxan (Rituximab) Biosimilar Market Forecast by Value (2018-2025)
  • The US Humira (Adalimumab) Biosimilar Market Forecast by Value (2018-2025)
  • The US Stelara (Ustekinumab) Biosimilar Market Forecast by Value (2023-2025)
  • The US Supportive Care Biosimilar Market Landscape
  • The US Oncology Biosimilar Market Landscape
  • The US Long Acting Insulin Biosimilar Market Landscape
  • The US Rapid Acting Insulin Biosimilar Market Landscape
  • The US Ophthalmology Biosimilar Market Landscape
  • The US TNF blockers Biosimilar Market Landscape
  • The US Supportive Care Biosimilar Pipeline Landscape
  • The US Oncology Biosimilar Pipeline Landscape
  • The US Insulin Biosimilar Pipeline Landscape
  • The US Ophthalmology Biosimilar Pipeline Landscape
  • The US TNF blockers Biosimilar Pipeline Landscape
  • The US Immunosuppressant Biosimilar Pipeline Landscape
  • The US Bone Health Biosimilar Pipeline Landscape
  • The US Growth Hormone Biosimilar Pipeline Landscape
  • The US Infertility Biosimilar Pipeline Landscape
  • The US Estimated New Cancer Cases in (2017-2021)
  • The US National Health Expenditure (2015-2020)
  • The US population 65 Years & Older (2020-2060)
  • Share of Health Plans Preferring Biosimilars Over Reference Product (2020)
  • North America Unique Parenteral Biologic Molecule LoP Events (2021-2030)
  • Key Players - Forecasted Market Share (2021- 2025)
  • Products
  • Celltrion, Inc. Sales and Net Profit (2017-2021)
  • Samsung Biologics Co., Ltd. Revenue and Profit (Loss) (2017-2021)
  • Samsung Biologics Co., Ltd. Revenue By Region (2021)
  • Amgen Inc. Total Revenues and Net Income (2017-2021)
  • Amgen Inc. Total Revenues By Region (2021)
  • Segments
  • Pfizer Inc. Revenues and Net Income (2017-2021)
  • Pfizer Inc. Revenues By Segment (2021)
  • Pfizer Inc. Revenues By Region (2021)
  • Segments
  • Novartis AG Net Sales and Net Income (2017-2021)
  • Novartis AG Net Sales by Segment (2021)
  • Novartis AG Net Sales by Region (2021)
  • Viatris Inc. Net Sales and Net (Loss) Earnings (2018-2021)
  • Viatris Inc. Net Sales by Segment (2021)

List of Tables

  • Difference between Biologics, Biosimilar and Generic Drugs
  • FDA-Approved Biosimilar Products
  • FDA-Approved Biosimilar Products (2020)
  • Key Players - Revenue Comparison (2021)
  • Key Players - Market Capitalization Comparison (2022)
  • FDA Approved Biosimilars- Key Players
  • Key Players - Biosimilar Cancellation Cases
  • Avastin (Bevacizumab) Biosimilar Developers
  • Prolia (Denosumab) Biosimilar Developers
  • Rituxan (Rituximab) Biosimilar Developers
  • Stelara (Ustekinumab) Biosimilar Developers
  • Humira (Adalimumab) Biosimilar Developers
  • Xolair (Omalizumab) Biosimilar Developers